Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Офтальмология / Английские материалы / Oxford American Handbook of Ophthalmology_Tsai, Denniston, Murray_2011

.pdf
Скачиваний:
0
Добавлен:
28.03.2026
Размер:
11 Mб
Скачать

406 CHAPTER 13 Medical retina

.

Anatomy and physiology

The retina is a remarkable modification of the embryonic forebrain that gathers light, codes the information as an electrical signal (transduces), and transmits it via the optic nerve to the processing areas of the brain.

Embryologically, it is derived from the optic vesicle (neuroectoderm), with an outer wall that becomes the retinal pigment epithelium, a potential space (the subretinal space), and an inner wall that becomes the neural retina.

Anatomy

Retinal pigment epithelium (RPE)

The RPE is a monolayer of hexagonal cells. The apices form microvilli that envelop the photoreceptor outer segments. Near the apices, adjacent RPE cells are joined by numerous tight junctions to form the outer blood– retinal barrier.

The base of the RPE is crenellated (to increase surface area) and mitochondrion rich. The basement membrane of the RPE forms the inner layer of Bruch’s membrane. Anteriorly, the RPE is continuous with the pigmented layer of the ciliary body.

Neural retina

This is a 150–400 μm thick layer of transparent neural tissue, comprising photoreceptors (rods, cones), integrators (bipolar, horizontal, amacrine, ganglion cells), the output pathway (nerve fiber layer), and the support cells (Müller cells). Anteriorly, the neural retina is continuous with the nonpigmented layer of the ciliary body.

The macula is defined histologically by a multilayered ganglion cell layer (i.e., more than one cell thick) and approximates to a 5500 μm oval centered on the fovea and bordered by the temporal arcades. It is yellowish from the presence of xanthophyll. The macula is further divided into perifovea (1500 μm wide band defined by 6 layers of bipolar cells), parafovea (500 μm wide band defined by 7–11 layers of bipolar cells), and fovea (1500 μm diameter circular depression). The fovea comprises a rim, a 22* slope, and a central floor, the foveola (350 μm diameter, 150 μm thin). The umbo is the center of the foveola (150 μm diameter); maximal cone density equates to highest acuity.

Blood supply

Branches of the ophthalmic artery include the central retinal artery, which supplies retinal circulation, and the three posterior ciliary arteries, which provide choroidal circulation. Anatomically, the retinal circulation supports the inner two-thirds of the retina, whereas the choroidal circulation supports the outer third; the watershed is at the outer plexiform layer. Physiologically, this equates to two-thirds of the retina’s oxygen and nutrient requirements being supplied by the choroidal circulation.

The retinal circulation comprises a small part of ocular blood flow (5%) but with a high level of oxygen extraction (40% arteriovenous difference), contrasting with figures of 85% and 5% for the choroidal circulation. In the retinal circulation, the arterial branches lie in the nerve fiber layer but give rise to both an inner capillary network (ganglion cell layer) and an outer

.

ANATOMY AND PHYSIOLOGY 407

capillary network (inner nuclear layer). However, there are no capillaries in the central 500 μm, the foveal avascular zone (FAZ).

The outer blood–retinal barrier is formed by the tight junctions of the RPE cells, whereas the inner is formed by the nonfenestrated endothelium of the retinal capillaries.

Physiology

RPE

The RPE is vital to the normal function of the neural retina. Functions include maintenance of the outer blood–retinal barrier, maintenance of retinal adhesion, nutrient supply to the photoreceptors, absorption of scattered excess light (by melanosomes), production and recycling of photopigments, and phagocytosis of damaged photoreceptor discs (each sheds >100 discs per day).

Neural retina

Each human eye contains around 120 million rods and 6.5 million cones. The rods subserve peripheral and low-light (scotopic) vision, whereas the cones permit normal (photopic), central, and color vision. The rods reach their highest density at 20* from the fovea, in contrast to blue cones, which are densest in the perifovea, and red and green cones, which are densest (up to 385,000/mm2) at the umbo.

The outer segments of photoreceptors contain transmembrane photopigment molecules (rhodopsin in rods, iodopsins in cones) that undergo cis-trans isomerization on absorption of a photon of light (440–450 nm for blue, 535–555 nm for green, and 570–590 nm for red cones).

Activation of a single photopigment molecule starts a cascade of activation (transducin activates phosphodiesterase which in turn hydrolyses cGMP) with 100-fold amplification at every stage. Falling cGMP levels cause closure of Na channels, with photoreceptor hyperpolarization. The resting potential is then restored by the action of recoverin, which activates guanylate cyclase to cGMP and reopen Na channels.

Rods synapse with “on” bipolar cells, which in turn synapse with amacrine and ganglion cells. Cones synapse with “on” and “off” bipolar cells, which in turn synapse with “on” and “off” ganglion cells. Negative feedback is provided by the laterally interacting horizontal cells (between photoreceptors) and amacrine cells (between bipolar cells and ganglion cells). This contributes to the center-surround phenomenon exhibited by ganglion cells in which they are activated by stimulation in the center of their receptive field but inhibited by stimulation of the surround. Ganglion cell representation is maximal at the fovea, where the cone: ganglion cell ratio approaches 1:1.

Ganglion cells are divided into two main populations. The parvocellular system subserves fine visual acuity and color. These cells are mainly foveal, have small receptive fields, and show spectral sensitivity. The magnocellular system subserves motion detection and coarser form vision. These ganglion cells are mainly peripheral, have larger receptive fields and high luminance and contrast (but no spectral) sensitivity, and are sensitive to motion. This division is preserved in the lateral geniculate nucleus (layers 1–2 magnocellular, 3–6 parvocellular) and visual cortex.

408 CHAPTER 13 Medical retina

.

Age-related macular degeneration (1)

Age-related macular degeneration (AMD) is the leading cause of blindness for those over age 50 in the Western world. Its prevalence increases with age. Estimates vary according to the exact definition of AMD. One study found visually significant disease (VA 20/30) in around 1% for age 55–65 years, 6% for 65–75 years, and 20% for >75 years.

Drusen (not necessarily with dVA) are increasingly common with age. Other risk factors include gender (female > male), ethnic origin (white >> black), diet, cardiovascular risk, smoking, pigmentary changes in the macula, family history of macular degeneration, and hypermetropia.

Non-neovascular (dry) AMD

Accounting for 90% of AMD, this tends to lead to gradual but potentially significant reduction in central vision. It is characterized by drusen (hard or soft) and RPE changes (focal hyperpigmentation or atrophy).

Histology

There is a gradual loss of the RPE/photoreceptor layers, thinning of the outer plexiform layer, thickening of Bruch’s membrane, and atrophy of choriocapillaris, exposing the larger choroidal vessels on examination.

Drusen are PAS-positive amorphous deposits lying between the RPE membrane and the inner collagenous layer of Bruch’s membrane; they may become calcified. Additional abnormal basement membrane deposit lies between the RPE membrane and RPE cells; it is not visible clinically.

Clinical features

dVA, metamorphopsia, scotomas; usually gradual in onset.

Hard drusen (small, well-defined, of limited significance), soft drusen (larger, poorly defined, increased risk of CNV), RPE focal hyperpigmentation, RPE atrophy (“geographic” if well-demarcated) (see Fig. 13.1).

Investigation

FA is not usually necessary. Fundus autofluorescence is useful for delineating the area of disease and following disease progression.

Treatment

Supportive: low vision aid counseling, and linking to support group and social services.

Refraction: with increased near-add; low-vision aid assessment and provision are often best arranged in a dedicated low-vision clinic.

Intraocular telescope: implantable telescope after cataract extraction can provide patients with moderate disease an enlarge image for reading daily activities within a 3 meters range; patient selection is highly important for this procedure.

Amsler grid: regular use of an Amsler grid allows the patient to detect new or progressive metamorphopsia, prompting him/her to seek ophthalmologic examination.

Lifestyle changes: vitamin supplementation (AREDS formula) and smoking cessation may slow progression.

AGE-RELATED MACULAR DEGENERATION (1) 409

.

Figure 13.1 Severe dry AMD with extensive area of large confluent drusen, pigmentary changes, and early RPE atrophy. See insert for color version.

410 CHAPTER 13 Medical retina

Age-related macular degeneration (2)

Neovascular (wet) AMD

Although much less common, neovascular AMD leads to rapid and severe loss of vision. It accounts for up to 90% of legal blindness due to AMD.

Histology

New fragile capillaries grow from the choriocapillaris through the damaged Bruch’s membrane and proliferate in the sub-RPE (type I membranes) and/ or subretinal space (type 2 membranes). There may be associated hemorrhage, exudation, retina or RPE detachment, or scar formation.

Type I membranes are more common in AMD with diffuse RPE and Bruch’s membrane disease; type 2 are more common in younger patients with focal disease of the RPE and Bruch’s membrane (e.g., with POHS).

Clinical features

dVA, metamorphopsia, scotoma; may be sudden in onset.

A gray membrane is sometimes visible; more commonly, it is deduced from associated signs, including subretinal (red) or sub-RPE (gray) hemorrhage (Fig. 13.2), subretinal/sub-RPE exudation, retinal or pigment epithelial detachment, CME, or subretinal fibrosis (disciform scar).

.

Figure 13.2 Neovascular AMD with a large choroidal neovascular complex and extensive subretinal and sub-RPE hemorrhage. See insert for color version.

AGE-RELATED MACULAR DEGENERATION (2) 411

Investigation

Urgent FA is vital for accurate diagnosis and plan for treatment.

Classic choroidal neovascular membrane (CNV): early well-demarcated lacy hyperfluorescence with progressive leakage (Fig. 13.3).

Occult CNV type I: fibrovascular pigment epithelial detachment seen as irregular elevation (on stereoscopic view) with stippled pinpoint hyperfluorescence beginning at 1–2 min post-injection (Fig. 13.4).

Occult CNV type II: late leakage of undetermined source, poorly demarcated hyperfluorescence 5–10 min post-injection.

.

Early phase: well-demarcted lacy hyperfluorescence

Late phase: progressive lakage

Figure 13.3 FA of classic choroidal neovascular membrane.

412 CHAPTER 13 Medical retina

Early phase: stippled hyperfluorescence usually maximal at 1–2 mi masking by blood adjacent to disc

.

Late phase: progressive leakage

Figure 13.4 FA of occult choroidal neovascular membrane.

Treatment

Supportive

Offer counseling, refraction, Amsler grid, and low-vision aids and encourage lifestyle changes as for non-neovascular AMD.

Laser photocoagulation (usually argon green)

Extrafoveal CNV—if well demarcated, treat with confluent burns over the whole lesion and up to 100 μm beyond its circumference.

Juxtafoveal CNV—if well demarcated, treat the parts away from the fovea as for extrafoveal CNV (i.e., up to 100 μm beyond the lesion), but on the foveal side only treat up to the perimeter of the lesion.

Consider anti-VEGF and PDT if this cannot be performed without significant risk to the fovea.

AGE-RELATED MACULAR DEGENERATION (2) 413

Photodynamic therapy (PDT)

For subfoveal CNV, if it is 100% classic or predominantly classic, then treat with photodynamic therapy. Also consider PDT for 100% occult lesions if CNV 4 DD in size and/or with a recent decrease in VA.

Anti-VEGF therapy

The two most commonly injected anti-VEGF drugs are ranibizumab (Lucentis) and bevacizumab (Avastin). Ranibizumab (Lucentis) is an FDAapproved murine antigen-binding (Fab) antibody fragment with high affinity for all isoforms of VEGF molecule. Bevacizumab is the full-length antibody for the VEGF molecule.

Ranibizumab is a humanized agent and further affinity maturated, giving ranibizumab a 20-fold higher binding affinity than that of bevacizumab. In the ANCHOR and MARINA clinical trials, intravitreal injections of ranibizumab helped 34–40% of patients with neovascular AMD regain vision. This benefit was sustained over the course of the 2-year study. This data was significantly better than the results achieved with PDT and intravitreal pegaptanib (Macugen).

.

414 CHAPTER 13 Medical retina

.

Age-related macular degeneration (3)

Differential diagnosis of CNV

Table 13.1 Common causes of CNV

Degenerative

AMD

 

Pathological myopia (lacquer crack)

 

Angioid streaks

Trauma

Choroidal rupture

 

Laser

Inflammation

POHS

 

Multifocal choroiditis

 

Serpiginous choroidopathy

 

Bird-shot retinochoroidopathy

 

Punctate inner choroidopathy

 

VKH

Dystrophies

Best’s disease

Other

Chorioretinal scar (any cause)

 

Tumor

Idiopathic

 

 

 

ANTI-VEGF THERAPY 415

Anti-VEGF therapy

Pegaptanib (Macugen) was the first FDA-approved anti-VEGF agent for the treatment of neovascular AMD. The drug is a 28-base ribonucleixribonucleotide aptamer, with high affinity for VEGF165 isoform. Two concurrent clinical trials (VISION trials) demonstrated that 70% of pegaptanib vs. 55% of sham injections lose <15 letters of visual acuity at 1 year. On average, the patient during the first 2 years of treatment continues to lose vision, although at a significantly slower rate.

Two additional anti-VEGF drugs are used for treatment of neovascular AMD, the FDA-approved ranibizumab and the off-label parent antibody molecule bevacizumab. Ranibizumab may offer several theoretical advantages over bevacizumab, such as deeper penetration of the retina (smaller molecule), higher binding affinity, and being less immunogenic. These theoretical advantages have yet to be proven in clinical application.

Any differences between the two anti-VEGF agents are likely to be small and may be demonstrated by the results of the ongoing CATT (Comparison of AMD Treatment Trial) study. Several phase III clinical trials (ANCHOR, MARINA, PIER) have demonstrated excellent success using ranibizumab to treat all angiographic forms of AMD. Exciting results included average increase of 6.5 ETDRS letters of improvement in 2 years of follow-up; 1 of 3 patients experienced improvement of 3 or more lines of vision at 2 years.

.

Risk of intravitreal anti-VEGF injections

Vitreous hemorrhage.

Intraocular inflammation (pseudo-endophthalmitis).

Infectious endophthalmitis.

Increase IOP.

Retinal detachment.

Traumatic cataract.

Theoretical risk of systemic vascular thrombosis.

Intravitreal injection of bevacizumab and ran-bizumab

Discus with the patient the risks and benefits of the procedure and obtain informed consent.

Procedure

Prepare the injection in a sterile environment.

Provide anesthesia (topical anesthesia, subconjunctival anesthesia).

Prepare the surgical area, including the eyelid, with 50% betadine.

Instill 50% betadine into the fornix.

Measure with caliper the location of the injection (3 mm in pseudophakic, 4 mm in phakic patients).

Firmly grasp the conjunctiva and inject 0.05cc of bevacizumab or ranbizumab.

Confirm arterial perfusion by vision evaluation or IOP check.

Give postoperative antibiotics per physician preference.